Open Access<p>β-Elemene Enhances the Chemotherapeutic Effect of 5-Fluorouracil in Triple-Negative Breast Cancer via PI3K/AKT, RAF-MEK-ErK, and NF-κB Signaling Pathways</p>
Author(s) -
Pengyu Su,
Bashir Ahmad,
Kun Zou,
Lijuan Zou
Publication year - 2020
Publication title -
oncotargets and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.054
H-Index - 60
ISSN - 1178-6930
DOI - 10.2147/ott.s242820
Subject(s) - mapk/erk pathway , pi3k/akt/mtor pathway , protein kinase b , cancer research , downregulation and upregulation , viability assay , chemistry , triple negative breast cancer , ly294002 , cell growth , apoptosis , signal transduction , biology , medicine , cancer , breast cancer , biochemistry , gene
The most common chemotherapeutic drug for triple-negative breast cancer (TNBC) treatment is 5-fluorouracil (5-FU), but its therapeutic index is low due to its toxicity. β-Elemene (ELE) possesses antitumor activity against different cancers, but it has never been used in combination with 5-FU to improve its chemotherapeutic effect against TNBC.